Cargando…
Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy
Desmoplastic and hypoxic pancreatic cancer microenvironment induces aberrant expression of miRNAs and hypoxia-inducible factor-1α (HIF-1α) responsible for gemcitabine (GEM) resistance. We demonstrated that miR-519c was down-regulated in pancreatic cancer and transfection of miR-519c in GEM-resistant...
Autores principales: | Xin, Xiaofei, Kumar, Virender, Lin, Feng, Kumar, Vinod, Bhattarai, Rajan, Bhatt, Vijaya R., Tan, Chalet, Mahato, Ram I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673723/ https://www.ncbi.nlm.nih.gov/pubmed/33177098 http://dx.doi.org/10.1126/sciadv.abd6764 |
Ejemplares similares
-
Gemcitabine elaidate and ONC201 combination therapy inhibits pancreatic cancer in a KRAS mutated syngeneic mouse model
por: Mahato, Ram, et al.
Publicado: (2023) -
Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice
por: Kumar, Virender, et al.
Publicado: (2018) -
Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC
por: Hong, Chen, et al.
Publicado: (2022) -
A Modular Coassembly Approach to All-In-One Multifunctional Nanoplatform for Synergistic Codelivery of Doxorubicin and Curcumin
por: Yang, Muyang, et al.
Publicado: (2018) -
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells
por: Papa, Anne-Laure, et al.
Publicado: (2012)